The Department of Health and Human Services and Department of Defense Oct. 9 announced support for AstraZeneca’s late-stage development and large-scale manufacturing of the AZD7442 investigational treatment for COVID-19.

AZD7442 is a cocktail of two monoclonal antibodies that may help treat or prevent infection with SARS-CoV-2. AstraZeneca will receive approximately $486 million under Operation Warp Speed for two Phase 3 clinical trials and related development activities, including a large-scale manufacturing demonstration project and supply of AZD7442 doses in the U.S.

Two other monoclonal antibody cocktails are currently in development, with candidates from Regeneron and Lilly. Both are undergoing clinical trials, with their respective makers also requesting emergency use authorizations from the Food and Drug Administration.

HHS and DOD said that effective monoclonal antibodies that can prevent COVID-19, particularly those that are long-lasting and delivered by intramuscular injection, “may be of particular use in certain groups. This includes people who have compromised immune function, those who are over 80 years old, and people undergoing medical treatments that preclude them from receiving a COVID-19 vaccine.”

Related News Articles

Headline
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce congue lorem nisl, ac dapibus dui vestibulum ut. Vivamus egestas at ipsum eget posuere.…
Headline
Moderna Inc. today announced that its mRNA-1273 vaccine candidate against COVID-19 is 94.5% effective, according to early data. The candidate is currently…
Headline
As of Nov. 6, about 60% of the nation’s retail pharmacies have agreed to participate in a federal program to administer COVID-19 vaccines at no cost to…
Perspective
“Don’t let perfect be the enemy of the good” is a quote credited to the French writer and thinker Voltaire. Although he died in 1778, that phrase is very…
Headline
To continue amplifying the important message of protecting against both the flu and COVID-19, AHA’s Wear A Mask and United Against the Flu campaigns today…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has released guidance on considerations for health…